Literature DB >> 34933912

Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-dependent Induction of Polo-Like Kinase 4.

Karuna Mittal1, Jaspreet Kaur1, Shaligram Sharma1, Nivya Sharma1, Guanhao Wei1, Ishita Choudhary1, Precious Imhansi-Jacob1, Nagini Maganti1, Shrikant Pawar1, Padmashree Rida2, Michael S Toss3, Mohammed Aleskandarany3, Emiel A Janssen4, Håvard Søiland5, Meenakshi V Gupta6, Michelle D Reid7, Emad A Rakha3, Ritu Aneja1.   

Abstract

Centrosome amplification (CA) has been implicated in the progression of various cancer types. Although studies have shown that overexpression of PLK4 promotes CA, the effect of tumor microenvironment on polo-like kinase 4 (PLK4) regulation is understudied. The aim of this study was to examine the role of hypoxia in promoting CA via PLK4. We found that hypoxia induced CA via hypoxia-inducible factor-1α (HIF1α). We quantified the prevalence of CA in tumor cell lines and tissue sections from breast cancer, pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, and prostate cancer and found that CA was prevalent in cells with increased HIF1α levels under normoxic conditions. HIF1α levels were correlated with the extent of CA and PLK4 expression in clinical samples. We analyzed the correlation between PLK4 and HIF1A mRNA levels in The Cancer Genome Atlas (TCGA) datasets to evaluate the role of PLK4 and HIF1α in breast cancer and PDAC prognosis. High HIF1A and PLK4 levels in patients with breast cancer and PDAC were associated with poor overall survival. We confirmed PLK4 as a transcriptional target of HIF1α and demonstrated that in PLK4 knockdown cells, hypoxia-mimicking agents did not affect CA and expression of CA-associated proteins, underscoring the necessity of PLK4 in HIF1α-related CA. To further dissect the HIF1α-PLK4 interplay, we used HIF1α-deficient cells overexpressing PLK4 and showed a significant increase in CA compared with HIF1α-deficient cells harboring wild-type PLK4. These findings suggest that HIF1α induces CA by directly upregulating PLK4 and could help us risk-stratify patients and design new therapies for CA-rich cancers. IMPLICATIONS: Hypoxia drives CA in cancer cells by regulating expression of PLK4, uncovering a novel HIF1α/PLK4 axis. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34933912      PMCID: PMC8983505          DOI: 10.1158/1541-7786.MCR-20-0798

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   6.333


  56 in total

1.  Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma.

Authors:  Karuna Mittal; Angela Ogden; Michelle D Reid; Padmashree C G Rida; Sooryanarayana Varambally; Ritu Aneja
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  SAPK pathways and p53 cooperatively regulate PLK4 activity and centrosome integrity under stress.

Authors:  Takanori Nakamura; Haruo Saito; Mutsuhiro Takekawa
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

3.  High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq.

Authors:  Johannes Schödel; Spyros Oikonomopoulos; Jiannis Ragoussis; Christopher W Pugh; Peter J Ratcliffe; David R Mole
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

4.  TRANSFAC: a database on transcription factors and their DNA binding sites.

Authors:  E Wingender; P Dietze; H Karas; R Knüppel
Journal:  Nucleic Acids Res       Date:  1996-01-01       Impact factor: 16.971

5.  Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1.

Authors:  Dong Hoon Shin; Yang-Sook Chun; Dong Soon Lee; L Eric Huang; Jong-Wan Park
Journal:  Blood       Date:  2008-01-03       Impact factor: 22.113

6.  HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions.

Authors:  Daniele Fanale; Viviana Bazan; Lidia Rita Corsini; Stefano Caruso; Lavinia Insalaco; Marta Castiglia; Giuseppe Cicero; Giuseppe Bronte; Antonio Russo
Journal:  Breast Cancer Res Treat       Date:  2013-08-08       Impact factor: 4.872

7.  Tumor-Derived Factors and Reduced p53 Promote Endothelial Cell Centrosome Over-Duplication.

Authors:  Zhixian Yu; Kevin P Mouillesseaux; Erich J Kushner; Victoria L Bautch
Journal:  PLoS One       Date:  2016-12-15       Impact factor: 3.240

8.  Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells.

Authors:  Karuna Mittal; Da Hoon Choi; Angela Ogden; Shashi Donthamsetty; Brian D Melton; Meenakshi V Gupta; Vaishali Pannu; Guilherme Cantuaria; Sooryanarayana Varambally; Michelle D Reid; Kristin Jonsdottir; Emiel A M Janssen; Mohammad A Aleskandarany; Ian O Ellis; Emad A Rakha; Padmashree C G Rida; Ritu Aneja
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

9.  p53-Dependent and cell specific epigenetic regulation of the polo-like kinases under oxidative stress.

Authors:  Alejandra Ward; John W Hudson
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

10.  A centrosome clustering protein, KIFC1, predicts aggressive disease course in serous ovarian adenocarcinomas.

Authors:  Karuna Mittal; Da Hoon Choi; Sergey Klimov; Shrikant Pawar; Ramneet Kaur; Anirban K Mitra; Meenakshi V Gupta; Ralph Sams; Guilherme Cantuaria; Padmashree C G Rida; Ritu Aneja
Journal:  J Ovarian Res       Date:  2016-03-18       Impact factor: 4.234

View more
  3 in total

Review 1.  Balancing the scales: fine-tuning Polo-like kinase 4 to ensure proper centriole duplication.

Authors:  John M Ryniawec; Gregory C Rogers
Journal:  Genes Dev       Date:  2022-06-01       Impact factor: 12.890

Review 2.  Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer.

Authors:  Nikita Jinna; Padmashree Rida; Max Smart; Mark LaBarge; Tijana Jovanovic-Talisman; Rama Natarajan; Victoria Seewaldt
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

3.  PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence.

Authors:  Chandra K Singh; Ryan A Denu; Minakshi Nihal; Maria Shabbir; Debra R Garvey; Wei Huang; Kenneth A Iczkowski; Nihal Ahmad
Journal:  Prostate       Date:  2022-03-25       Impact factor: 4.012

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.